NASDAQ:ABIO - ARCA biopharma, Inc.
$6.85
 $-0.05
-0.70%
11:55AM EDT
2019-07-22
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ABIO     avg for
industry  
  avg for
sector  
42 stocks weight:  21. 81   217. 37   399. 45  
42 stocks rank:  3. 12 K 1. 27 K 716. 99  
# analyst opinions:  1. 00   13. 21   13. 71  

quick ratio:  6. 22   5. 49   1. 88  
current ratio:  6. 61   5. 87   2. 36  

target price low:  17. 00   83. 44   114. 90  
target price avg:  17. 00   106. 20   137. 90  
target price high:  17. 00   132. 30   158. 97  
1-yr high:  18. 36   111. 86   142. 57  
last close:  6. 90   86. 79   125. 44  
50-day avg:  7. 51   86. 68   122. 63  
200-day avg:  8. 27   89. 22   121. 38  
1-yr low:  5. 04   69. 78   100. 51  
volume:  20. 41 K 2. 62 M 3. 43 M
50-day avg volume:  247. 10 K 3. 20 M 4. 16 M
200-day avg volume:  530. 65 K 2. 99 M 4. 75 M

1-day return:  -0. 29 % -1. 30 % -0. 99 %
this week return:  0. 88 % 0. 45 % -0. 20 %
12-wk return:  27. 78 % 0. 94 % 4. 84 %
52-wk return:  -32. 55 % -1. 30 % 10. 55 %

enterprise value (EV):  -364. 19 K 45. 10 B 122. 38 B
market cap:  10. 04 M 38. 96 B 108. 40 B
EBITDA:  -7. 11 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  0. 05   5. 38   11. 93  
total debt:  60. 00 K 10. 90 B 17. 48 B
debt/equity:  0. 82   57. 18   120. 05  
net income (common):  -6. 86 M 2. 07 B 4. 05 B

shares outstanding:  773. 56 K 538. 09 M 1. 24 B
shares:  1. 09 M 548. 00 M 1. 22 B
shares short:  52. 37 K 10. 98 M 11. 87 M
shares short prior month:  44. 42 K 9. 32 M 12. 05 M
short ratio:  0. 15   5. 60   3. 34  
short % of float:  5. 19 % 6. 48 % 2. 64 %
total cash/share:  7. 29   10. 98   9. 19  
total cash:  8. 01 M 5. 93 B 6. 10 B
free cash flow:  -4. 57 M 2. 92 B 4. 55 B
operating cash flow:  -6. 74 M 3. 80 B 5. 78 B

book value:  6. 66   13. 35   27. 45  
price/book:  1. 04   4. 60   8. 78  
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -8. 53   2. 10   4. 23  
forward EPS:  -15. 42   3. 45   7. 10  
P/E:  -0. 81   1. 90   32. 10  
forward P/E:  -0. 45   6. 46   15. 47  
PE/G:  0. 02   0. 70   -0. 54  
growth:  -48. 12 % 265. 63 % 79. 11 %
earnings high:  -1. 86   0. 89   1. 68  
earnings avg:  -1. 86   0. 70   1. 57  
earnings low:  -1. 86   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -41. 64 % -2. 34 % 5. 28 %
return on equity:  -74. 70 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  0. 28   1. 27   0. 91  
sharpe (1yr):  0. 42   0. 16   0. 77  

held % insiders:  0. 83 % 6. 06 % 3. 29 %
held % institutions:  10. 85 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : ABIO
.    106.552 =       106.552 :: --> INITIAL WEIGHT <--
.    - 8.533 =        98.019 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.967 =       192.849 :: P/E factor
.    x 2.209 =       425.995 :: PE/G factor
.    x 1.417 =       603.625 :: beta factor
.    x 0.789 =       476.081 :: sharpe factor
.    x 2.873 =      1367.717 :: current ratio factor
.    x 1.092 =       1493.08 :: quick ratio factor
.    x 2.117 =      3160.574 :: short ratio factor
.    x 1.005 =      3176.904 :: price-to-book factor
.    x 4.559 =     14485.026 :: EBITDA factor
.    x 1.005 =     14553.501 :: EBITDA vs industry factor
.    x 1.007 =     14657.479 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      31085.48 :: sector+industry 1-year gains factor
.    x 1.009 =     31378.556 :: industry 12-weeks return factor
.    x 1.308 =     41039.655 :: industry 2-weeks return factor
.    x 0.998 =     40971.983 :: "drift" penalty 2 days ago
.    x 0.975 =     39947.157 :: "drift" penalty 4 days ago
.    / 2.192 =     18225.643 :: overall "drift" factor
.     x 0.64 =     11664.025 :: largest single-day jump factor
.    x 0.097 =      1134.633 :: low price factor
.    x 1.839 =      2086.582 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.419 =       873.487 :: forward EPS factor
.    x 0.789 =       688.953 :: forward P/E factor
.    x 1.185 =       816.211 :: industry recommendation factor
.    x 1.003 =       818.468 :: factor historical industry gain for week 29
.    x 11.41 =      9338.365 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =          9.83 :: reduced for readability
.   + 11.984 =        21.814 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     21.814 :: FINAL WEIGHT for NASDAQ:ABIO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org